Network Point of Care Glucose Testing Market

The market for Network Point of Care Glucose Testing was estimated at $1.5 billion in 2025; it is anticipated to increase to $1.9 billion by 2030, with projections indicating growth to around $2.4 billion by 2035.

Report ID:DS1801034

Author:Debadatta Patel - Senior Consultant

Published Date:December 2024

Datatree

Life Science

Medical Device

Network Point of Care Glucose Testing

Customization Available

Network Point of Care Glucose Testing - 2025-2035

Market Outlook
Market Key Insights
Growth Opportunity
Market Dynamics
Application
Recent Development
Impact Analysis

Report Summary

Market Data

Methodology

Table of Contents

Report Summary

Market Data

Methodology

Table of Contents

Global Network Point of Care Glucose Testing Market Outlook

Revenue, 2025

$1.5B

Forecast, 2035

$2.4B

CAGR, 2026 - 2035

4.7%

The Network Point of Care Glucose Testing industry revenue is expected to be around $1.5 billion in 2026 and expected to showcase growth with 4.7% CAGR between 2026 and 2035. The development path shows Network Point Of Care Glucose Testing establishing itself as an essential tool for diabetes treatment in both hospital based and ongoing patient care environments. The adoption of glucose monitoring systems occurs primarily in hospitals and long term care facilities because these institutions represent 80.9% of total implementation. The adoption of bedside glucose monitoring and connected point of care systems has become standard practice for hospital glucose management and long term care diabetes monitoring operations. The market demand stems from healthcare organizations which want to improve their clinical operations and minimize drug related mistakes and deliver value based patient care. The market generated $1.13 billion in revenue from portable analyzers during 2025 because healthcare organizations choose mobile solutions which integrate with their current health IT systems and fulfill evolving regulatory requirements.

The Point Of Care Glucose Testing market uses portable or cart based glucose meters which work with centralized data management software and wireless connectivity and laboratory information systems and electronic health records interfaces to provide real time data analytics and closed loop decision support. The system provides fast results together with automated quality checks and user verification and it generates combined reports which show blood sugar levels throughout different hospital region's. The market segment serves multiple essential purposes which include hospital blood sugar management and surgical patient monitoring and acute care decision support and long term disease management initiatives. The segment functions as a fundamental part of the complete point of care testing market. The market demand for networked glucose testing solutions has increased because of recent developments which include remote patient monitoring platform integration and enhanced cybersecurity standards and interoperability requirements and analytical systems for insulin dosing optimization. The strategic value of digitally enabled glucose testing solutions has increased because of these recent market developments.

Network Point of Care Glucose Testing market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035 — Network Point of Care Glucose Testing Market Outlook

Market Key Insights

The Network Point of Care Glucose Testing market is projected to grow from $1.5 billion in 2025 to $2.4 billion in 2035. This represents a CAGR of 4.7%, reflecting rising demand across Remote Patient Monitoring, Real-time Data Sharing with Healthcare Providers, and Healthcare Research and Analytics.
The market leaders Abbott LLC and Nova Biomedical and Danaher operate as major competitors which determine the competitive dynamics of this industry.
The Network Point of Care Glucose Testing market shows its top markets exist in U.S. and Germany which will experience 3.3% to 4.3% annual growth rates from 2025 to 2030.
The research predicts Brazil, India and Saudi Arabia will experience the most significant market expansion at rates between 5.2% and 6.6% CAGR.
The Transition to Non Invasive Technologies holds more power in the United States and Germany market value chain because it will generate $36 million of new value for Network Point of Care Glucose Testing industry revenue during 2030.
The Network Point of Care Glucose Testing market will experience a $0.9 billion growth span from 2025 to 2035 while manufacturers focus on Hospital & Clinics Application to achieve higher market penetration.
The Network Point of Care Glucose Testing market will experience a 58% expansion from 2025 to 2035 because diabetes cases continue to increase while glucose testing technology improves.

Network Point of Care Glucose Testing - Country Share Analysis

Opportunities in the Network Point of Care Glucose Testing

The integration of Network Point Of Care Glucose Testing into home care systems through connected ecosystems allows for immediate glucose tracking of patients who need insulin and elderly people. The market for portable networked meters will also experience most of its expansion because payers will use incentives to move chronic disease management away from hospital settings. The need for home healthcare devices which offer intuitive operation and reimbursement capabilities and interoperability exists because of digital health platform integration with remote patient monitoring systems and hospital at home programs in North America.

Growth Opportunities in North America and Asia-Pacific

The Network Point Of Care Glucose Testing market in North America shows both established market characteristics and ongoing technological advancement because hospitals maintain their position as leading end users because they perform numerous tests and need to connect their systems with electronic medical records platforms. The market demand grows because of increasing diabetes cases and healthcare organizations now reward value based care and hospitals need to reduce patient stays which drives companies to spend money on connected point of care glucose analyzers that enable POC glucose testing and immediate clinical choices. The market competition remains high because multinational companies protect their market position through their connected platforms and secure devices and business service agreements while smaller competitors focus on workflow automation and analytics. The company should focus on three strategic opportunities which involve creating high end bedside glucose testing solutions for big integrated delivery networks and developing subscription services for long term care facilities and working with hospital networks to establish standardized formularies and test interoperability systems.

The Network Point Of Care Glucose Testing market in Asia Pacific shows growing diversity because clinics and mid sized hospitals represent the primary customer base because of increasing outpatient services and restricted laboratory facilities in secondary cities and changing diagnostic practices toward decentralized testing. The market experiences growth because of three main factors which include rising diabetes cases and public initiatives to increase primary healthcare services and people choosing budget friendly quick blood glucose tests that minimize their need for laboratory testing. The market competition involves worldwide brands which compete against budget friendly local manufacturers who focus on creating durable products at affordable prices and easy to learn testing systems for untrained personnel. The company should develop multiple product lines which serve different customer spending ranges while creating customized network solutions for complex IT systems and forming alliances with primary care organizations and telemedicine services to integrate POC glucose monitoring into disease management protocols for chronic patients.

Market Dynamics and Supply Chain

Driver: Growing Prevalence of Diabetes and Expanding Telehealth Adoption Driving Market Growth

The rising global prevalence of diabetes, driven by aging populations, sedentary lifestyles, and increasing obesity rates, significantly fuels demand for network point of care glucose testing. More individuals require frequent glucose monitoring, pushing healthcare systems to adopt efficient, connected solutions that reduce the burden on traditional labs. At the same time, the rapid expansion of telehealth services has also accelerated adoption of networked glucose monitoring technologies. Telemedicine platforms increasingly rely on CGM devices and connected glucometers that transmit real‑time data to clinicians, enabling remote management and reducing hospital visits. Integration with mobile health applications and cloud‑based analytics further improves patient engagement by providing personalized alerts and actionable insights. These dual trends are also reshaping care delivery by connecting patients and providers, enhancing adherence, reducing complication rates, and supporting proactive interventions that improve clinical outcomes and lower overall healthcare costs.

Technological innovation in connected continuous glucose monitoring systems and smart point of care glucose monitoring platforms is also a key driver of market growth. Modern devices offer seamless wireless connectivity, real‑time data sharing with healthcare providers, and interoperability with electronic health records and mobile apps. Improved sensor accuracy, longer wear times, and intuitive user interfaces enhance patient compliance and clinician confidence. These advancements support predictive analytics, personalized treatment adjustments, and integration with broader digital health ecosystems, making networked glucose testing indispensable for contemporary diabetes care management.

Restraint: Data Privacy Concerns and Regulatory Compliance Challenges Slowing Adoption

Network point of care glucose testing relies on real‑time transmission of patient data, raising privacy and compliance concerns that can restrain market growth. Strict regulations like HIPAA in the U.S. and GDPR in Europe require secure data handling and consent management. Healthcare providers may delay or limit deployment due to fear of breaches or non‑compliance, reducing demand for connected systems. For example, smaller clinics often avoid cloud‑connected CGM platforms to minimize legal risk, impacting revenue for device makers.

Opportunity: Integrating Network Point Of Care Glucose Testing into hospital critical-care workflows across rapidly modernizing Asian markets and Deploying Network Point Of Care Glucose Testing for community clinics serving low-income diabetic populations in Africa

The hospital environments of acute and critical care now use Network Point Of Care Glucose Testing which has transitioned from independent meters to complete networked benchtop analyzers that connect to laboratory information systems. The market for benchtop platforms will expand from 0.40 billion in 2025 to 0.47 billion by 2030 with 3.25% CAGR while leading the fastest growth in Asia Pacific through its use in intensive care and perioperative settings. The hospital point of care testing programs receive complete network connectivity which enables better protocol compliance and clinical decision support tool operation for standardized glucose management protocols that meet audit requirements in emergency departments and high acuity wards.

The urban and peri urban region's of Africa need affordable Network Point Of Care Glucose Testing because their large diabetic population lacks proper medical care in community clinics and pharmacies. The opportunity depends on portable connected devices which use cellular or smartphone gateways to send encrypted results to central locations for monitoring and payment processing. The implementation of customized rugged analyzers with battery efficiency and multilingual interfaces and flexible consumable pricing by vendors will enable public private screening programs to achieve volume expansion. The fastest growth in primary care and outreach applications will occur because governments focus on delivering equal glycemic control through decentralized healthcare systems.

Challenge: High Cost of Connected Glucose Monitoring Technology Limiting Accessibility

Advanced network‑enabled glucose testing solutions, such as continuous glucose monitors with wireless connectivity, often come with higher upfront and maintenance costs compared to traditional glucometers. This cost barrier limits adoption in low‑income regions and among price‑sensitive patients. For instance, premium CGM subscriptions and smartphone integration fees can deter users, reducing overall uptake and slowing market expansion despite clinical advantages.

Supply Chain Landscape

Sensor Manufacturing

DanaherNova Biomedical

Device Assembly

Abbott LLCF. Hoffmann-La Roche Ltd.Ascensia Diabetes Care Holdings AG

Network Integration

Abbott LLCDanaher

Clinical End-Users

Hospitals & ClinicsDiagnostic LaboratoriesHome Healthcare

Sensor Manufacturing

DanaherNova Biomedical

Device Assembly

Abbott LLCF. Hoffmann-La Roche Ltd.Ascensia Diabetes Care Holdings AG

Network Integration

Abbott LLCDanaher

Clinical End-Users

Hospitals & ClinicsDiagnostic LaboratoriesHome Healthcare

Network Point of Care Glucose Testing - Supply Chain

Use Cases of Network Point of Care Glucose Testing in Remote Patient Monitoring & Real-time Data Sharing with Healthcare Providers

Remote Patient Monitoring : Network point of care glucose testing plays a pivotal role in remote patient monitoring by enabling real‑time glucose tracking for individuals with diabetes outside traditional clinical settings. Wearable continuous glucose monitoring (CGM) systems and connected glucometers transmit glucose data via secure networks to healthcare platforms, supporting remote clinicians in assessing trends and adjusting treatment plans quickly. Leading providers like Dexcom, Abbott (FreeStyle Libre), Medtronic, and Roche Diagnostics dominate this space with reliable connectivity, long sensor wear times, and intuitive mobile apps. Their strength lies in seamless integration with telehealth systems, enabling proactive interventions and improved glycemic control while reducing hospital visits. These solutions enhance patient engagement by providing alerts and insights directly to patients and care teams, strengthening adherence and self‑management in home and community settings.

Real-time Data Sharing with Healthcare Providers : In the application of real‑time data sharing with healthcare providers, network‑enabled glucose testing solutions facilitate instant access to glucose readings for clinicians, allowing immediate adjustments to medication, lifestyle recommendations, or emergency responses. Connected CGM platforms and smart point of care glucometers share cloud‑based data with electronic health records and clinician dashboards in secure formats. Dexcom G series, Abbott FreeStyle Libre 3, and Roche Accu‑Chek Connect are leading systems offering robust interoperability and analytics features. Their market leadership stems from strong partnerships with health systems, regulatory approvals for accuracy, and expansive digital ecosystems. This connectivity supports collaborative decision‑making between patients and caregivers and enhances continuity of care across outpatient and inpatient environments, increasing efficiency and reducing complications from delayed responses.

Healthcare Research and Analytics : Network point of care glucose testing also significantly contributes to healthcare research and analytics by aggregating large volumes of anonymized glucose data for population health insights, clinical studies, and predictive modeling. Platforms that integrate CGM and smart glucometer data with analytics engines enable researchers to understand trends in glycemic variability, treatment effectiveness, and correlations with other health metrics. Major players such as Dexcom, Abbott, Medtronic, and Roche support research initiatives through data platforms and partnerships with academic institutions and pharmaceutical companies. Their advanced analytics capabilities and cloud infrastructure empower big data analysis, machine learning applications, and epidemiological research, driving innovations in diabetes care protocols and personalized medicine. These contributions enhance evidence‑based decision‑making, accelerate clinical trial outcomes, and support public health strategies.

Recent Developments

Network point of care glucose testing is advancing with connected continuous glucose monitoring, real‑time data integration, and predictive analytics, enhancing chronic disease management and remote care delivery. A key trend is the use of AI‑driven algorithms to forecast glucose fluctuations and personalize treatment plans, improving clinical decision support. Integration with telehealth platforms and mobile health apps strengthens patient engagement and facilitates proactive interventions, driving adoption among healthcare providers and individuals managing diabetes.

August 2025 : Abbott introduced the next‑generation FreeStyle Libre 2 Plus, providing real‑time glucose readings every minute with optional alarms, enhancing point of care and home monitoring for people with diabetes.

March 2025 : Nova Biomedical expanded its StatStrip Glucose Hospital Meter System with broader critical care use authorization in the U.S., marking one of the most approved POC glucose meters for hospital networks.

Impact of Industry Transitions on the Network Point of Care Glucose Testing Market

As a core segment of the Medical Device industry, the Network Point of Care Glucose Testing market develops in line with broader industry shifts. Over recent years, transitions such as Transition to Non-Invasive Technologies and Adoption of AI and Big Data Analytics have redefined priorities across the Medical Device sector, influencing how the Network Point of Care Glucose Testing market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

Transition to Non-Invasive Technologies

The Network Point Of Care Glucose Testing market experiences a critical transformation because non invasive glucose monitoring systems now replace conventional finger stick glucose testing methods throughout the United States and Germany. The market will achieve an additional USD 36 million in revenue through 2030 because patients want painless continuous monitoring and healthcare providers need efficient workflow systems which will drive the adoption of skin patch glucose sensors and optical glucose sensors. The market will experience progressive growth because innovators who merge non invasive point of care glucose testing with connected systems will achieve higher market value through their ability to generate premium prices and recurring consumable sales and enhanced clinical decision support from data analysis. The existing invasive medical device market will experience rapid declining profit margins and possible market position deterioration because of this development.

Adoption of AI and Big Data Analytics

The network point of care glucose testing market is increasingly embracing AI and big data analytics to improve diabetes management and patient outcomes. Connected CGM devices and smart glucometers now leverage predictive algorithms to analyze glucose patterns in real time, enabling early detection of hyperglycemic or hypoglycemic events. These insights support personalized care plans, optimized insulin dosing, and lifestyle recommendations. The transition has also impacted telehealth services, digital health platforms, and healthcare analytics, as providers integrate patient-generated glucose data into electronic health records and population health dashboards. Pharmaceutical companies and research institutions benefit from aggregated, anonymized datasets to develop targeted therapies, enhance clinical trials, and identify trends in glycemic control, driving innovation across the broader healthcare ecosystem while improving patient engagement and adherence.